Page last updated: 2024-08-25

zoledronic acid and Low Bone Density

zoledronic acid has been researched along with Low Bone Density in 90 studies

Research

Studies (90)

Timeframe	Studies, this research(%)	All Research%
pre-1990	0 (0.00)	18.7374
1990's	2 (2.22)	18.2507
2000's	22 (24.44)	29.6817
2010's	53 (58.89)	24.3611
2020's	13 (14.44)	2.80

Authors

Authors	Studies
Bhattacharjee, R; Singhania, P	1
Barroso, J; Edwards, WB; Haider, IT; Schnitzer, TJ; Simonian, N	1
Biggs, AE; Damron, TA; Mann, KA; Oest, ME; Sweeney-Ambros, AR; Zimmerman, ND	1
Pu, D; Xie, LL; Yu, H; Yuan, X	1
Brockstedt, HK; Harsløf, T; Langdahl, B; Sølling, AS	1
Lane, JM; Levin, JE; Nieves, JW; Tutaworn, T; Wang, Z; Yoo, JE	1
Barroso, J; Crack, LE; Edwards, WB; Gabel, L; Haider, IT; Schnitzer, TJ; Simonian, N	1
Ding, Y; Fu, GT; Li, CC; Lin, LJ; Lin, SP; Liu, S; Shen, J; Sheng, PY; Wang, K; Xue, YL; Zhang, JX; Zheng, QJ	1
Bastin, S; Gamble, GD; Garratt, E; Horne, AM; Mihov, B; Reid, IR; Stewart, A	1
Bastin, S; Gamble, GD; Horne, AM; Mihov, B; Reid, IR; Stewart, A	1
Bolland, M; Gamble, G; Grey, A; Horne, A; Mihov, B; Reid, IR	1
Formal, CS; Leiby, BE; Marino, RJ; Modlesky, CM; Oleson, CV	1
Cheng, YT; Hong, W; Huo, H; Liao, DJ; Liao, J; Ma, H; Tang, ZL; Zellmer, L; Zhou, Q	1
Briody, J; Emmanuel, J; Gryllakis, J; Heather, N; Jefferies, C; Lee, KJ; Lim, A; Munns, CF; Pitkin, J; Siafarikas, A; Simm, PJ; Wang, X; Zacharin, M	1
Chen, Q; Dong, J; Jiang, L; Lin, H; Liu, W; Xing, R; Yasen, M; Yishake, M	1
Aro, E; Aro, HT; Mattila, K; Moritz, N	1
Brüel, A; Thomsen, JS; Vegger, JB	1
Carr, A; Ebeling, PR; Hoy, JF; Kerr, SJ; Martinez, E; Pocock, N; Richardson, R; Rojas, J	1
Goenka, S; Jindal, R; Joshi, M; Pandey, N; Sethi, S	1
Rosen, CJ	1
Leong, I	1
Bastin, S; Bolland, MJ; Gamble, GD; Garratt, E; Horne, AM; Mihov, B; Reid, IR; Stewart, A; Wiessing, KR; Wong, S	1
Bastin, S; Bolland, MJ; Gamble, GD; Garratt, E; Horne, AM; Mihov, B; Reid, IR; Stewart, A; Wiessing, KR	1
Hagino, N; Nango, E; Suzuki, S	1
Tufan, F	1
Chattopadhyay, A; Jain, S	1
Gamble, GD; Horne, AM; Reid, IR	1
de Jongh, RT; Smit, DL; Zillikens, MC	1
Janovszky, Á; Kaszaki, J; Ocsovszki, I; Piffkó, J; Pócs, L; Szabó, A	1
Crandall, CJ; Ensrud, KE	1
Brasure, M; Butler, M; Ensrud, KE; Fink, HA; Forte, ML; MacDonald, R; Nelson, VA; Olson, CM; Rosebush, CE; Schousboe, JT; Taylor, BC; Ullman, K; Wilt, TJ	1
Horne, AM; Mihov, B; Reid, IR	1
Bonnet, N; Ferrari, S; Lesclous, P; Saffar, JL	1
Cure, E; Cure, MC; Yuce, S	1
Bolland, M; Gamble, G; Grey, A; Horne, A; Mihov, B; Reid, IR; Wong, S	1
Khajuria, DK; Mahapatra, DR; Razdan, R	1
Brüel, A; Nielsen, ES; Thomsen, JS; Vegger, JB	1
Bauman, WA; Cirnigliaro, CM; Kirshblum, SC; La Fountaine, MF; Martinez, L; Spungen, AM	1
Al-Abuwsi, F; Bolland, M; Horne, A; McGhee, CN; Nisa, Z; Patel, DV; Reid, IR; Singh, M	1
Edwards, S; Elford, C; Evans, BA; Fogelman, I; Frost, ML; Hampson, G; Ishtiaq, S; Sankaralingam, A	1
Hashimoto, A; Horiguchi, H; Ibata, S; Iyama, S; Kamihara, Y; Kato, J; Kobune, M; Ono, K; Sato, T; Takada, K; Takimoto, R; Tatekoshi, A	1
Bernstein, A; Nelson, K; Poxleitner, PJ; Schmelzeisen, R; Stadelmann, V; Stoddart, MJ; Voss, PJ; Ziebart, T	1
Cheung, MS	1
Atherton, PJ; Dakhil, SR; Hines, SL; Lafky, JM; Loprinzi, CL; Majithia, N; Olson, J; Perez, EA; Wagner-Johnston, N	1
Cunneen, TS; Goold, LA; Leibovitch, I; Martin, P; Pirbhai, A; Rajak, SN; Selva, D; Wilcsek, G	1
Bergmaier, V; El-Shafi, N; Flügge, T; Hövener, JB; Ludwig, U; Poxleitner, P; Stadelmann, V; von Elverfeldt, D; Voss, P	1
Mészaros, Á; Veszelyné Kotán, E	1
Cong, J; Cui, M; Sun, J; Wang, LJ; Yu, LZ; Zhang, N	1
Chen, H; Ma, H; Ma, J; Wang, P; Zhang, H; Zhang, Y; Zhao, X; Zhou, C; Zhu, Y	1
Anderson, KC; Lerman, MA; Lyng, GD; Sonis, ST; Watkins, BA	1
Bjelic-Radisic, V; Dubsky, P; Fitzal, F; Gnant, M; Greil, R; Jakesz, R; Kainberger, F; Kässmann, H; Kubista, E; Luschin-Ebengreuth, G; Marth, C; Menzel, C; Mittlböck, M; Mlineritsch, B; Piswanger-Sölkner, JC; Ploner, F; Samonigg, H; Seifert, M; Steger, G; Wohlmuth, P	1
Fernandez, S; Huang, J; McCutchan, JA; Meixner, L	1
Azizkhan, RG; Heubi, JE; Lucky, AW; Perman, MJ	1
Baba, S; Bessho, H; Hayakawa, K; Ishiyama, H; Iwamura, M; Kimura, M; Matsumoto, K; Okusa, H; Satoh, T; Tabata, K	1
Tamási, L	1
Atherton, PJ; Dakhil, SR; Dalton, RJ; Hines, SL; Johnson, DB; Loprinzi, CL; Mattar, BI; Perez, EA; Reddy, PS; Sloan, JA	1
Bhoopalam, N; Campbell, SC; Ellis, NK; Friedman, N; Garewal, H; Iyer, P; Moritz, TE; Pandya, M; Reda, DJ; Thottapurathu, L; Vanveldhuizen, P; Warren, SR	1
Civantos Modino, S; Díaz Guardiola, P; Guijarro de Armas, MG; Montaño Martínez, JM; Pavón de Paz, I; Zubieta Tabernero, J	1
Tan, WW	1
Azouz, EM; Forget, S; Laforte, D; Rodd, C; Sbrocchi, AM	1
Brufsky, AM	1
Black, DM; Bucci-Rechtweg, C; Grbic, JT; Lyles, KW; McClung, M; Orwoll, E; Reid, DM; Su, G	1
Polyzos, SA	1
Argüelles Jiménez, I; Carrillo García, P; García Fernández, H; Quevedo Juanals, J; Serra Soler, G	1
Adler, G; Haenle, MM; Klaus, J; Reinshagen, M; Schröter, C; von Boyen, G; von Tirpitz, C	1
Botteman, MF; Carter, JA; Joshi, AD; Kaura, S	1
Bensimon, AG; Ericson, SG; Guo, A; Marynchenko, M; Namjoshi, M; Raje, N; Wu, EQ; Yu, AP	1
Bhattacharyya, I; Bowers, LM; Cohen, DM; Fitzpatrick, SG; Green, JG; Hinkson, DW; Neuman, AN; Stavropoulos, MF	1
Bartl, R	1
Bolland, M; Gamble, G; Grey, A; Horne, A; Reid, IR; Wong, S	1
Bolland, MJ; Gamble, G; Grey, A; Horne, A; House, M; Reid, IR; Wattie, D	1
Arranz Caso, JA; Dominguez-Mompello, JL; Flores Ballester, E; López Pizarro, V; Ngo Pombe, S; Restoy Lozano, A	1
Bilston, LE; Briody, JN; Cowell, CT; Gardiner, EM; Little, DG; Smith, EJ; Smith, NC; Williams, PR	1
Davis, LE; Li, EC	1
Hershman, D; Narayanan, R	1
Berenson, JR	1
Barone, A; Foppiani, L; Palummeri, E; Prete, C; Senesi, B; Trasciatti, S; Veneziano, M	1
Parles, K	1
Lipton, A	1
Boulet, JM; Bunton, TE; Sellers, R; Walker, K; Whiteside, GT	1
Soileau, KM	1
Bowden, DK; Crawford, BA; Gilfillan, CP; Kean, AM; Obaid, M; Rodda, CP; Strauss, BJ	1
Godfrey, C; Little, DG; McDonald, M; Mikulec, K; Morse, A; Ramachandran, M; Schindeler, A	1
Brown, JE; Coleman, RE; Ellis, SP; Gutcher, S; Khanna, T; Lester, JE; McCloskey, E; Purohit, OP	1
Hadji, P	1
Blunn, GW; Coathup, MJ; Goodship, AE; Green, J	1
Bundred, N; Hadji, P	1
Hay, JE	1
Bogoch, ER; Moran, EL; Pysklywec, MW	1
Binkley, N; Bruner, J; Davidowitz, B; Green, J; Haffa, A; Kimmel, D; Meng, C; Schaffer, V	1

Reviews

16 review(s) available for zoledronic acid and Low Bone Density

Article	Year
A review of the zoledronic acid combined with percutaneous vertebroplasty in the osteoporotic vertebral compression fracture. Asian journal of surgery, 2023, Volume: 46, Issue:1 Topics: Bone Diseases, Metabolic; Fractures, Compression; Humans; Lumbar Vertebrae; Spinal Fractures; Treatment Outcome; Vertebroplasty; Zoledronic Acid	2023
Long-Term Drug Therapy and Drug Discontinuations and Holidays for Osteoporosis Fracture Prevention: A Systematic Review. Annals of internal medicine, 2019, 07-02, Volume: 171, Issue:1 Topics: Alendronate; Bone Density; Bone Density Conservation Agents; Bone Diseases, Metabolic; Diphosphonates; Drug Administration Schedule; Duration of Therapy; Female; Hip Fractures; Humans; Osteoporosis, Postmenopausal; Osteoporotic Fractures; Spinal Fractures; Zoledronic Acid	2019
Drugs Used in Paediatric Bone and Calcium Disorders. Endocrine development, 2015, Volume: 28 Topics: Acetazolamide; Bone and Bones; Bone Density Conservation Agents; Bone Diseases, Metabolic; Calcitonin; Calcitriol; Calcium; Child; Denosumab; Diphosphonates; Diuretics; Glucocorticoids; Humans; Hypercalcemia; Hyperphosphatemia; Hypocalcemia; Hypophosphatemia; Imidazoles; Osteoporosis; Parathyroid Hormone; Phosphates; Risedronic Acid; Sodium Potassium Chloride Symporter Inhibitors; Vitamin D; Zoledronic Acid	2015
Bisphosphonate-Induced Orbital Inflammation: A Case Series and Review. Orbit (Amsterdam, Netherlands), 2015, Volume: 34, Issue:6 Topics: Aged; Aged, 80 and over; Alendronate; Bone Density Conservation Agents; Bone Diseases, Metabolic; Diphosphonates; Female; Humans; Imidazoles; Male; Middle Aged; Orbital Cellulitis; Orbital Myositis; Pamidronate; Radiography; Retrospective Studies; Zoledronic Acid	2015
[Therapeutic practice of bisphosphonate use and related pharmaceutical issues I]. Acta pharmaceutica Hungarica, 2016, Volume: 86, Issue:1 Topics: Alendronate; Bone Density Conservation Agents; Bone Diseases, Metabolic; Bone Neoplasms; Clodronic Acid; Diphosphonates; Fractures, Bone; Humans; Hungary; Ibandronic Acid; Imidazoles; Osteoporosis; Pamidronate; Risedronic Acid; Zoledronic Acid	2016
Efficacy and safety of medical therapy for low bone mineral density in patients with Crohn disease: A systematic review with network meta-analysis. Medicine, 2017, Volume: 96, Issue:11 Topics: Alendronate; Bayes Theorem; Bone Density; Bone Density Conservation Agents; Bone Diseases, Metabolic; Crohn Disease; Diphosphonates; Humans; Imidazoles; Network Meta-Analysis; Risedronic Acid; Sodium Fluoride; Zoledronic Acid	2017
[Antitumor activity of zoledronic acid]. Magyar onkologia, 2009, Volume: 53, Issue:3 Topics: Animals; Antineoplastic Agents; Bone Density Conservation Agents; Bone Diseases, Metabolic; Bone Neoplasms; Diphosphonates; Evidence-Based Medicine; Humans; Imidazoles; Lung Neoplasms; Treatment Outcome; Zoledronic Acid	2009
The evolving role of bone-conserving therapy in patients with breast cancer. Seminars in oncology, 2010, Volume: 37 Suppl 1 Topics: Bone Density Conservation Agents; Bone Diseases, Metabolic; Bone Neoplasms; Breast Neoplasms; Clodronic Acid; Diphosphonates; Female; Humans; Imidazoles; Survival Analysis; Zoledronic Acid	2010
[Bisphosphonate related osteonecrosis of the jaw and infection with Actinomyces]. Medicina clinica, 2012, Dec-15, Volume: 139, Issue:15 Topics: Actinomyces; Actinomycosis; Aged; Aged, 80 and over; Alendronate; Anti-Bacterial Agents; Bisphosphonate-Associated Osteonecrosis of the Jaw; Bone Density Conservation Agents; Bone Diseases, Metabolic; Combined Modality Therapy; Diphosphonates; Disease Susceptibility; Etidronic Acid; Female; Humans; Imidazoles; Male; Mandibular Diseases; Maxillary Diseases; Middle Aged; Models, Biological; Neoplasms; Osteitis; Osteoporosis; Retrospective Studies; Risedronic Acid; Zoledronic Acid	2012
Zoledronic acid: a new parenteral bisphosphonate. Clinical therapeutics, 2003, Volume: 25, Issue:11 Topics: Animals; Bone Diseases, Metabolic; Bone Neoplasms; Clinical Trials as Topic; Diphosphonates; Half-Life; Humans; Hypercalcemia; Imidazoles; Metabolic Clearance Rate; Neoplasms; Zoledronic Acid	2003
Prevention and management of osteoporosis in women with breast cancer and men with prostate cancer. Current oncology reports, 2004, Volume: 6, Issue:4 Topics: Absorptiometry, Photon; Alendronate; Antineoplastic Agents; Bone Density; Bone Density Conservation Agents; Bone Diseases, Metabolic; Breast Neoplasms; Calcitonin; Calcium; Clodronic Acid; Diphosphonates; Drug Therapy, Combination; Estrogens; Etidronic Acid; Female; Humans; Imidazoles; Male; Osteoporosis; Prostatic Neoplasms; Quality of Life; Risedronic Acid; Risk Factors; Treatment Outcome; Vitamin D; Zoledronic Acid	2004
Recommendations for zoledronic acid treatment of patients with bone metastases. The oncologist, 2005, Volume: 10, Issue:1 Topics: Bone Diseases, Metabolic; Bone Neoplasms; Clinical Trials as Topic; Creatinine; Diphosphonates; Humans; Imidazoles; Infusions, Intravenous; Kidney; Practice Guidelines as Topic; Zoledronic Acid	2005
Primary hyperparathyroidism and neuropsychiatric alterations in a nonagenarian woman. Aging clinical and experimental research, 2005, Volume: 17, Issue:1 Topics: Aged; Aged, 80 and over; Bone Diseases, Metabolic; Cognition Disorders; Diphosphonates; Disease Progression; Diuretics; Female; Humans; Hypercalcemia; Hyperparathyroidism; Imidazoles; Nervous System Diseases; Sodium Chloride; Treatment Outcome; Zoledronic Acid	2005
New therapeutic agents for the treatment of bone diseases. Expert opinion on biological therapy, 2005, Volume: 5, Issue:6 Topics: Antineoplastic Agents; Bone Density Conservation Agents; Bone Diseases; Bone Diseases, Metabolic; Bone Neoplasms; Bone Resorption; Breast Neoplasms; Diphosphonates; Humans; Ibandronic Acid; Imidazoles; Pamidronate; Randomized Controlled Trials as Topic; Zoledronic Acid	2005
Reducing the risk of bone loss associated with breast cancer treatment. Breast (Edinburgh, Scotland), 2007, Volume: 16 Suppl 3 Topics: Aromatase Inhibitors; Bone Density Conservation Agents; Bone Diseases, Metabolic; Bone Resorption; Breast Neoplasms; Chemotherapy, Adjuvant; Clinical Trials as Topic; Diphosphonates; Female; Fractures, Bone; Humans; Imidazoles; Risk Factors; Women's Health; Zoledronic Acid	2007
Reducing the risk of cancer treatment-associated bone loss in patients with breast cancer. Seminars in oncology, 2007, Volume: 34, Issue:6 Suppl 4 Topics: Aromatase Inhibitors; Bone Density Conservation Agents; Bone Diseases, Metabolic; Bone Resorption; Breast Neoplasms; Chemotherapy, Adjuvant; Clinical Trials as Topic; Diphosphonates; Female; Fractures, Bone; Humans; Imidazoles; Risk Factors; Zoledronic Acid	2007

Trials

28 trial(s) available for zoledronic acid and Low Bone Density

Article	Year
Zoledronic acid after spinal cord injury mitigates losses in proximal femoral strength independent of ambulation ability. Osteoporosis international : a journal established as result of cooperation between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA, 2023, Volume: 34, Issue:9 Topics: Absorptiometry, Photon; Bone Density; Bone Diseases, Metabolic; Femur; Femur Neck; Humans; Spinal Cord Injuries; Walking; Zoledronic Acid	2023
Effects of Zoledronate on Cancer, Cardiac Events, and Mortality in Osteopenic Older Women. Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research, 2020, Volume: 35, Issue:1 Topics: Aged; Bone Density; Bone Diseases, Metabolic; Breast Neoplasms; Double-Blind Method; Female; Heart Neoplasms; Humans; Zoledronic Acid	2020
Zoledronate Slows Weight Loss and Maintains Fat Mass in Osteopenic Older Women: Secondary Analysis of a Randomized Controlled Trial. Calcified tissue international, 2020, Volume: 106, Issue:4 Topics: Age Distribution; Aged; Alendronate; Bone Density; Bone Density Conservation Agents; Bone Diseases, Metabolic; Female; Humans; Middle Aged; Osteoporosis, Postmenopausal; Weight Loss; Zoledronic Acid	2020
Ten Years of Very Infrequent Zoledronate Therapy in Older Women: An Open-Label Extension of a Randomized Trial. The Journal of clinical endocrinology and metabolism, 2020, 04-01, Volume: 105, Issue:4 Topics: Aged; Bone Density Conservation Agents; Bone Diseases, Metabolic; Cohort Studies; Double-Blind Method; Female; Follow-Up Studies; Humans; Middle Aged; Osteoporosis, Postmenopausal; Prognosis; Time Factors; Zoledronic Acid	2020
The effect of zoledronic acid on attenuation of bone loss at the hip and knee following acute traumatic spinal cord injury: a randomized-controlled study. Spinal cord, 2020, Volume: 58, Issue:8 Topics: Acute Disease; Adult; Aged; Bone Density; Bone Density Conservation Agents; Bone Diseases, Metabolic; Double-Blind Method; Female; Femur; Humans; Male; Middle Aged; Pelvic Bones; Spinal Cord Injuries; Young Adult; Zoledronic Acid	2020
Randomized Controlled Trial Evaluating the Use of Zoledronic Acid in Duchenne Muscular Dystrophy. The Journal of clinical endocrinology and metabolism, 2021, 07-13, Volume: 106, Issue:8 Topics: Absorptiometry, Photon; Adolescent; Bone Density; Bone Density Conservation Agents; Bone Diseases, Metabolic; Bone Remodeling; Calcium; Child; Humans; Lumbar Vertebrae; Male; Muscular Dystrophy, Duchenne; Treatment Outcome; Vitamin D; Zoledronic Acid	2021
A long-lasting bisphosphonate partially protects periprosthetic bone, but does not enhance initial stability of uncemented femoral stems: A randomized placebo-controlled trial of women undergoing total hip arthroplasty. Journal of biomechanics, 2018, 06-25, Volume: 75 Topics: Absorptiometry, Photon; Aged; Aged, 80 and over; Arthroplasty, Replacement, Hip; Bone Density; Bone Density Conservation Agents; Bone Diseases, Metabolic; Double-Blind Method; Female; Femur; Humans; Middle Aged; Osseointegration; Radiostereometric Analysis; Zoledronic Acid	2018
Zoledronic acid is superior to tenofovir disoproxil fumarate-switching for low bone mineral density in adults with HIV. AIDS (London, England), 2018, 09-10, Volume: 32, Issue:14 Topics: Absorptiometry, Photon; Adult; Aged; Anti-HIV Agents; Australia; Bone Density; Bone Density Conservation Agents; Bone Diseases, Metabolic; Drug Substitution; Female; Femur Neck; HIV Infections; Humans; Lumbar Vertebrae; Male; Middle Aged; Spain; Tenofovir; Treatment Outcome; Viral Load; Zoledronic Acid	2018
Effect of early treatment with zoledronic acid on prevention of bone loss in patients with acute spinal cord injury: a randomized controlled trial. Spinal cord, 2018, Volume: 56, Issue:12 Topics: Absorptiometry, Photon; Adult; Bone Density; Bone Density Conservation Agents; Bone Diseases, Metabolic; Female; Femur; Hip; Humans; Male; Spinal Cord Injuries; Time Factors; Treatment Outcome; Zoledronic Acid	2018
Fracture Prevention with Zoledronate in Older Women with Osteopenia. The New England journal of medicine, 2018, 12-20, Volume: 379, Issue:25 Topics: Acute-Phase Reaction; Aged; Bone Density; Bone Density Conservation Agents; Bone Diseases, Metabolic; Bone Remodeling; Calcium; Dietary Supplements; Double-Blind Method; Female; Fractures, Bone; Humans; Infusions, Intravenous; Intention to Treat Analysis; Iritis; Proportional Hazards Models; Zoledronic Acid	2018
Anti-fracture efficacy of zoledronate in subgroups of osteopenic postmenopausal women: secondary analysis of a randomized controlled trial. Journal of internal medicine, 2019, Volume: 286, Issue:2 Topics: Aged; Bone Density; Bone Density Conservation Agents; Bone Diseases, Metabolic; Double-Blind Method; Female; Humans; Osteoporosis, Postmenopausal; Osteoporotic Fractures; Postmenopause; Prospective Studies; Zoledronic Acid	2019
[Zoledronic acid; useful in osteopenia?] Nederlands tijdschrift voor geneeskunde, 2019, 03-14, Volume: 163 Topics: Aged; Bone Density; Bone Density Conservation Agents; Bone Diseases, Metabolic; Denmark; Double-Blind Method; Female; Follow-Up Studies; Fractures, Bone; Humans; Incidence; Time Factors; Zoledronic Acid	2019
Duration of antiresorptive effects of low-dose zoledronate in osteopenic postmenopausal women: a randomized, placebo-controlled trial. Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research, 2014, Volume: 29, Issue:1 Topics: Aged; Bone Density; Bone Diseases, Metabolic; Bone Resorption; Collagen Type I; Diphosphonates; Double-Blind Method; Female; Hip; Humans; Imidazoles; Middle Aged; Osteoporosis, Postmenopausal; Peptide Fragments; Peptides; Procollagen; Spine; Zoledronic Acid	2014
Incidence of ocular side effects with intravenous zoledronate: secondary analysis of a randomized controlled trial. Osteoporosis international : a journal established as result of cooperation between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA, 2015, Volume: 26, Issue:2 Topics: Acute Disease; Bone Density; Bone Density Conservation Agents; Bone Diseases, Metabolic; Diphosphonates; Double-Blind Method; Female; Humans; Imidazoles; Incidence; Infusions, Intravenous; Middle Aged; Postmenopause; Prospective Studies; Scleritis; Treatment Outcome; Uveitis, Anterior; Zoledronic Acid	2015
The effect of nitrogen containing bisphosphonates, zoledronate and alendronate, on the production of pro-angiogenic factors by osteoblastic cells. Cytokine, 2015, Volume: 71, Issue:2 Topics: Alendronate; Angiopoietin-1; Animals; Bone Density; Bone Density Conservation Agents; Bone Diseases, Metabolic; Calcitriol; Cell Line; Cell Line, Tumor; Culture Media, Conditioned; Diphosphonates; Enzyme-Linked Immunosorbent Assay; Female; Gene Expression; Humans; Imidazoles; Mice; Middle Aged; Osteoblasts; Osteoporosis, Postmenopausal; Peptide Fragments; Procollagen; Reverse Transcriptase Polymerase Chain Reaction; Time Factors; Vascular Endothelial Growth Factor A; Zoledronic Acid	2015
Adjuvant endocrine therapy plus zoledronic acid in premenopausal women with early-stage breast cancer: 5-year follow-up of the ABCSG-12 bone-mineral density substudy. The Lancet. Oncology, 2008, Volume: 9, Issue:9 Topics: Adult; Anastrozole; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols; Bone Density; Bone Density Conservation Agents; Bone Diseases, Metabolic; Breast Neoplasms; Chemotherapy, Adjuvant; Diphosphonates; Female; Goserelin; Humans; Imidazoles; Linear Models; Nitriles; Osteoporosis; Premenopause; Prospective Studies; Tamoxifen; Triazoles; Zoledronic Acid	2008
A double-blinded, randomized controlled trial of zoledronate therapy for HIV-associated osteopenia and osteoporosis. AIDS (London, England), 2009, Jan-02, Volume: 23, Issue:1 Topics: Adult; Biomarkers; Bone Density; Bone Density Conservation Agents; Bone Diseases, Metabolic; Bone Remodeling; Calcium, Dietary; Diphosphonates; Double-Blind Method; Female; Hip Joint; HIV Infections; Humans; Imidazoles; Lumbar Vertebrae; Male; Middle Aged; Osteoporosis; Treatment Outcome; Zoledronic Acid	2009
Single infusion of zoledronic acid to prevent androgen deprivation therapy-induced bone loss in men with hormone-naive prostate carcinoma. Cancer, 2009, Aug-01, Volume: 115, Issue:15 Topics: Aged; Aged, 80 and over; Androgen Antagonists; Bone Density; Bone Density Conservation Agents; Bone Diseases, Metabolic; Diphosphonates; Humans; Imidazoles; Male; Middle Aged; Pilot Projects; Prostatic Neoplasms; Zoledronic Acid	2009
Zoledronic acid for treatment of osteopenia and osteoporosis in women with primary breast cancer undergoing adjuvant aromatase inhibitor therapy. Breast (Edinburgh, Scotland), 2010, Volume: 19, Issue:2 Topics: Aromatase Inhibitors; Bone Density; Bone Density Conservation Agents; Bone Diseases, Metabolic; Breast Neoplasms; Chemotherapy, Adjuvant; Diphosphonates; Female; Humans; Imidazoles; Letrozole; Nitriles; Osteoporosis; Risk Factors; Treatment Outcome; Triazoles; Zoledronic Acid	2010
Zoledronic acid for the treatment of osteopenia in pediatric Crohn's disease. Pediatrics international : official journal of the Japan Pediatric Society, 2010, Volume: 52, Issue:5 Topics: Adolescent; Analysis of Variance; Bone Density; Bone Diseases, Metabolic; Child; Crohn Disease; Diphosphonates; Dose-Response Relationship, Drug; Double-Blind Method; Drug Administration Schedule; Female; Follow-Up Studies; Humans; Imidazoles; Injections, Intravenous; Male; Prospective Studies; Reference Values; Statistics, Nonparametric; Time Factors; Treatment Outcome; Zoledronic Acid	2010
The incidence of osteonecrosis of the jaw in patients receiving 5 milligrams of zoledronic acid: data from the health outcomes and reduced incidence with zoledronic acid once yearly clinical trials program. Journal of the American Dental Association (1939), 2010, Volume: 141, Issue:11 Topics: Biomarkers; Bone Density Conservation Agents; Bone Diseases, Metabolic; Bone Resorption; Collagen Type I; Databases as Topic; Diphosphonates; Female; Follow-Up Studies; Forecasting; Humans; Imidazoles; Incidence; Jaw Diseases; Male; Osteonecrosis; Osteoporosis, Postmenopausal; Peptides; Placebos; Prevalence; Risk Factors; United States; Zoledronic Acid	2010
A single dose of intravenous zoledronate prevents glucocorticoid therapy-associated bone loss in acute flare of Crohn's disease, a randomized controlled trial. The American journal of gastroenterology, 2011, Volume: 106, Issue:4 Topics: Absorptiometry, Photon; Adult; Bone Density; Bone Density Conservation Agents; Bone Diseases, Metabolic; Crohn Disease; Diphosphonates; Double-Blind Method; Drug Administration Schedule; Female; Follow-Up Studies; Glucocorticoids; Humans; Imidazoles; Lumbar Vertebrae; Male; Severity of Illness Index; Treatment Outcome; Zoledronic Acid	2011
Cost-effectiveness of zoledronic acid in the management of skeletal metastases in patients with lung cancer in France, Germany, Portugal, the Netherlands, and the United kingdom. Clinical therapeutics, 2011, Volume: 33, Issue:3 Topics: Bone and Bones; Bone Density Conservation Agents; Bone Diseases, Metabolic; Bone Neoplasms; Carcinoma, Non-Small-Cell Lung; Combined Modality Therapy; Cost-Benefit Analysis; Diphosphonates; Europe; Fractures, Bone; Health Care Costs; Humans; Hypercalcemia; Imidazoles; Lung Neoplasms; Middle Aged; Quality-Adjusted Life Years; Spinal Cord Compression; Zoledronic Acid	2011
Low-dose zoledronate in osteopenic postmenopausal women: a randomized controlled trial. The Journal of clinical endocrinology and metabolism, 2012, Volume: 97, Issue:1 Topics: Aged; Algorithms; Bone Density; Bone Density Conservation Agents; Bone Diseases, Metabolic; Diphosphonates; Dose-Response Relationship, Drug; Double-Blind Method; Female; Humans; Imidazoles; Middle Aged; Osteoporosis, Postmenopausal; Placebos; Postmenopause; Spine; Zoledronic Acid	2012
Five years of anti-resorptive activity after a single dose of zoledronate--results from a randomized double-blind placebo-controlled trial. Bone, 2012, Volume: 50, Issue:6 Topics: Aged; Biomarkers; Bone Density; Bone Density Conservation Agents; Bone Diseases, Metabolic; Bone Remodeling; Bone Resorption; Collagen Type I; Diphosphonates; Double-Blind Method; Female; Humans; Imidazoles; Middle Aged; Peptide Fragments; Peptides; Procollagen; Time Factors; Zoledronic Acid	2012
A randomized, double-blind, placebo-controlled trial of intravenous zoledronic acid in the treatment of thalassemia-associated osteopenia. Calcified tissue international, 2006, Volume: 79, Issue:3 Topics: Adolescent; Adult; Alkaline Phosphatase; beta-Thalassemia; Bone Density; Bone Density Conservation Agents; Bone Diseases, Metabolic; Diphosphonates; Double-Blind Method; Female; Humans; Imidazoles; Male; Zoledronic Acid	2006
Prolonged efficacy of a single dose of the bisphosphonate zoledronic acid. Clinical cancer research : an official journal of the American Association for Cancer Research, 2007, Sep-15, Volume: 13, Issue:18 Pt 1 Topics: Absorptiometry, Photon; Adult; Aged; Bone and Bones; Bone Density; Bone Density Conservation Agents; Bone Diseases, Metabolic; Diphosphonates; Female; Humans; Imidazoles; Male; Middle Aged; Neoplasms; Zoledronic Acid	2007
How effective is bisphosphonate treatment for preventing bone fractures after liver transplantation? Nature clinical practice. Gastroenterology & hepatology, 2008, Volume: 5, Issue:4 Topics: Absorptiometry, Photon; Adult; Biomarkers; Body Mass Index; Bone Density Conservation Agents; Bone Diseases, Metabolic; Calcium Carbonate; Cholecalciferol; Diphosphonates; Female; Fractures, Bone; Humans; Imidazoles; Liver Transplantation; Male; Middle Aged; Prospective Studies; Treatment Outcome; Zoledronic Acid	2008

Other Studies

46 other study(ies) available for zoledronic acid and Low Bone Density

Article	Year
Letter to the Editor Regarding "Durability and Delayed Treatment Effects of Zoledronic Acid on Bone Loss After Spinal Cord Injury: A Randomized, Controlled Trial". Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research, 2022, Volume: 37, Issue:1 Topics: Bone Diseases, Metabolic; Diphosphonates; Humans; Spinal Cord Injuries; Time-to-Treatment; Zoledronic Acid	2022
Reply to Letter to the Editor Regarding "Durability and Delayed Treatment Effects of Zoledronic Acid on Bone Loss After Spinal Cord Injury: A Randomized, Controlled Trial". Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research, 2022, Volume: 37, Issue:1 Topics: Bone Diseases, Metabolic; Diphosphonates; Humans; Spinal Cord Injuries; Time-to-Treatment; Zoledronic Acid	2022
Orchestrated delivery of PTH [1-34] followed by zoledronic acid prevents radiotherapy-induced bone loss but does not abrogate marrow damage. Journal of orthopaedic research : official publication of the Orthopaedic Research Society, 2022, Volume: 40, Issue:12 Topics: Animals; Bone Density; Bone Density Conservation Agents; Bone Diseases, Metabolic; Bone Marrow; Humans; Mice; Parathyroid Hormone; Zoledronic Acid	2022
Discontinuation of denosumab in men with prostate cancer. Osteoporosis international : a journal established as result of cooperation between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA, 2023, Volume: 34, Issue:2 Topics: Androgen Antagonists; Androgens; Bone Density; Bone Density Conservation Agents; Bone Diseases, Metabolic; Denosumab; Humans; Male; Prostatic Neoplasms; Retrospective Studies; Zoledronic Acid	2023
Bone loss after denosumab discontinuation is prevented by alendronate and zoledronic acid but not risedronate: a retrospective study. Osteoporosis international : a journal established as result of cooperation between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA, 2023, Volume: 34, Issue:3 Topics: Alendronate; Bone Density; Bone Density Conservation Agents; Bone Diseases, Metabolic; Denosumab; Diphosphonates; Female; Humans; Lumbar Vertebrae; Osteoporosis, Postmenopausal; Retrospective Studies; Risedronic Acid; Spinal Fractures; Zoledronic Acid	2023
Efficiency of Zoledronic Acid in Inhibiting Accelerated Periprosthetic Bone Loss After Cementless Total Hip Arthroplasty in Osteoporotic Patients: A Prospective, Cohort Study. Orthopaedic surgery, 2019, Volume: 11, Issue:4 Topics: Adult; Aged; Arthroplasty, Replacement, Hip; Bone Density; Bone Density Conservation Agents; Bone Diseases, Metabolic; Calcium; Disease Progression; Female; Humans; Male; Middle Aged; Osteoporosis; Prospective Studies; Vitamin D; Zoledronic Acid	2019
Zoledronic acid modulates osteoclast apoptosis through activation of the NF-κB signaling pathway in ovariectomized rats. Experimental biology and medicine (Maywood, N.J.), 2021, Volume: 246, Issue:15 Topics: Animals; Apoptosis; Bone Density; Bone Diseases, Metabolic; Bone Resorption; Cell Differentiation; Female; NF-kappa B; Osteoclasts; Osteogenesis; Osteoporosis; Ovariectomy; Rats, Sprague-Dawley; Signal Transduction; Zoledronic Acid	2021
Effects of combined teriparatide and zoledronic acid on posterior lumbar vertebral fusion in an aged ovariectomized rat model of osteopenia. Journal of orthopaedic research : official publication of the Orthopaedic Research Society, 2018, Volume: 36, Issue:3 Topics: Animals; Bone Density; Bone Density Conservation Agents; Bone Diseases, Metabolic; Drug Evaluation, Preclinical; Drug Therapy, Combination; Female; Lumbar Vertebrae; Ovariectomy; Rats, Sprague-Dawley; Spinal Fusion; Teriparatide; X-Ray Microtomography; Zoledronic Acid	2018
Zoledronic acid prevents disuse osteopenia and augments gene expression of osteoclastic differentiation markers in mice. Journal of musculoskeletal & neuronal interactions, 2018, 06-01, Volume: 18, Issue:2 Topics: Animals; Bone Density; Bone Density Conservation Agents; Bone Diseases, Metabolic; Botulinum Toxins, Type A; Cancellous Bone; Cell Differentiation; Female; Femur; Gene Expression; Mice; Osteoclasts; X-Ray Microtomography; Zoledronic Acid	2018
A Not-So-New Treatment for Old Bones. The New England journal of medicine, 2018, 12-20, Volume: 379, Issue:25 Topics: Bone and Bones; Bone Diseases, Metabolic; Female; Fractures, Bone; Humans; Zoledronic Acid	2018
Zoledronate prevents fractures in osteopenia. Nature reviews. Endocrinology, 2018, Volume: 14, Issue:12 Topics: Aged; Bone Diseases, Metabolic; Female; Fractures, Bone; Humans; Zoledronic Acid	2018
Fracture Prevention with Zoledronate in Older Women with Osteopenia. The New England journal of medicine, 2019, 03-28, Volume: 380, Issue:13 Topics: Aged; Bone Diseases, Metabolic; Diphosphonates; Female; Fractures, Bone; Humans; Zoledronic Acid	2019
Fracture Prevention with Zoledronate in Older Women with Osteopenia. The New England journal of medicine, 2019, 03-28, Volume: 380, Issue:13 Topics: Aged; Bone Diseases, Metabolic; Diphosphonates; Female; Fractures, Bone; Humans; Zoledronic Acid	2019
Fracture Prevention with Zoledronate in Older Women with Osteopenia. The New England journal of medicine, 2019, 03-28, Volume: 380, Issue:13 Topics: Aged; Bone Diseases, Metabolic; Diphosphonates; Female; Fractures, Bone; Humans; Zoledronic Acid	2019
Fracture Prevention with Zoledronate in Older Women with Osteopenia. Reply. The New England journal of medicine, 2019, 03-28, Volume: 380, Issue:13 Topics: Aged; Bone Diseases, Metabolic; Diphosphonates; Female; Fractures, Bone; Humans; Zoledronic Acid	2019
Microcirculatory consequences of limb ischemia/reperfusion in ovariectomized rats treated with zoledronic acid. Journal of orthopaedic surgery and research, 2019, Apr-04, Volume: 14, Issue:1 Topics: Animals; Bone Density Conservation Agents; Bone Diseases, Metabolic; CD11b Antigen; Cell Adhesion; Female; Hindlimb; Microcirculation; Neutrophils; Ovariectomy; Periosteum; Rats, Sprague-Dawley; Reperfusion Injury; Zoledronic Acid	2019
In older postmenopausal women with osteopenia, zoledronate reduced fragility fractures at 6 years. Annals of internal medicine, 2019, 04-16, Volume: 170, Issue:8 Topics: Aged; Bone Diseases, Metabolic; Female; Fractures, Bone; Humans; Postmenopause; Zoledronic Acid	2019
Effect of Zoledronate on Bone Loss After Romosozumab/Denosumab: 2-Year Follow-up. Calcified tissue international, 2019, Volume: 105, Issue:1 Topics: Antibodies, Monoclonal; Bone Density; Bone Density Conservation Agents; Bone Diseases, Metabolic; Denosumab; Follow-Up Studies; Humans; Zoledronic Acid	2019
Zoledronate effects on systemic and jaw osteopenias in ovariectomized periostin-deficient mice. PloS one, 2013, Volume: 8, Issue:3 Topics: Animals; Bone and Bones; Bone Density; Bone Density Conservation Agents; Bone Diseases, Metabolic; Bone Remodeling; Bone Resorption; Cell Adhesion Molecules; Diphosphonates; Female; Imidazoles; Jaw; Mice; Mice, Knockout; Ovariectomy; Tomography, X-Ray Computed; Zoledronic Acid	2013
Severe hypocalcemia associated with zoledronic acid treatment in a patient with a risk of fracture due to drug-induced osteopenia. Minerva endocrinologica, 2013, Volume: 38, Issue:2 Topics: Absorptiometry, Photon; Bone Density; Bone Density Conservation Agents; Bone Diseases, Metabolic; Diphosphonates; Female; Fractures, Bone; Humans; Hypocalcemia; Imidazoles; Lupus Erythematosus, Systemic; Middle Aged; Risk; Zoledronic Acid	2013
Zoledronic acid in combination with alfacalcidol has additive effects on trabecular microarchitecture and mechanical properties in osteopenic ovariectomized rats. Journal of orthopaedic science : official journal of the Japanese Orthopaedic Association, 2014, Volume: 19, Issue:4 Topics: Animals; Biomechanical Phenomena; Bone and Bones; Bone Density Conservation Agents; Bone Diseases, Metabolic; Diphosphonates; Disease Models, Animal; Drug Synergism; Drug Therapy, Combination; Female; Humans; Hydroxycholecalciferols; Imidazoles; Osteoporosis, Postmenopausal; Ovariectomy; Rats; Rats, Wistar; Zoledronic Acid	2014
Additive effect of PTH (1-34) and zoledronate in the prevention of disuse osteopenia in rats. Bone, 2014, Volume: 66 Topics: Absorptiometry, Photon; Animals; Biomechanical Phenomena; Bone and Bones; Bone Diseases, Metabolic; Diphosphonates; Drug Synergism; Female; Imaging, Three-Dimensional; Imidazoles; Muscular Disorders, Atrophic; Parathyroid Hormone; Rats, Wistar; X-Ray Microtomography; Zoledronic Acid	2014
Zoledronic acid administration failed to prevent bone loss at the knee in persons with acute spinal cord injury: an observational cohort study. Journal of bone and mineral metabolism, 2015, Volume: 33, Issue:4 Topics: Absorptiometry, Photon; Adolescent; Adult; Bone and Bones; Bone Density; Bone Diseases, Metabolic; Diphosphonates; Female; Femur; Humans; Imidazoles; Knee; Male; Middle Aged; Prospective Studies; Spinal Cord Injuries; Tibia; Young Adult; Zoledronic Acid	2015
Markers of bone metabolism in multiple myeloma patients switched from zoledronic acid to denosumab. [Rinsho ketsueki] The Japanese journal of clinical hematology, 2014, Volume: 55, Issue:11 Topics: Acid Phosphatase; Adult; Aged; Aged, 80 and over; Alkaline Phosphatase; Antibodies, Monoclonal, Humanized; Biomarkers; Bone Density Conservation Agents; Bone Diseases, Metabolic; Bone Resorption; Calcium; Cell Differentiation; Collagen Type I; Denosumab; Diphosphonates; Drug Substitution; Female; Humans; Imidazoles; Isoenzymes; Male; Middle Aged; Multiple Myeloma; Myeloma Proteins; Osteoblasts; Osteocalcin; Osteogenesis; Peptides; RANK Ligand; Retrospective Studies; Tartrate-Resistant Acid Phosphatase; Zoledronic Acid	2014
Zoledronate induces bisphosphonate-related osteonecrosis of the jaw in osteopenic sheep. Clinical oral investigations, 2016, Volume: 20, Issue:1 Topics: Animals; Bisphosphonate-Associated Osteonecrosis of the Jaw; Bone Diseases, Metabolic; Dexamethasone; Diphosphonates; Disease Models, Animal; Female; Imidazoles; Ovariectomy; Random Allocation; Sheep, Domestic; Tooth Extraction; Wound Healing; Zoledronic Acid	2016
Zoledronic acid for treatment of osteopenia and osteoporosis in women with primary breast cancer undergoing adjuvant aromatase inhibitor therapy: a 5-year follow-up. Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer, 2016, Volume: 24, Issue:3 Topics: Adjuvants, Pharmaceutic; Aged; Aged, 80 and over; Aromatase Inhibitors; Bone Density; Bone Density Conservation Agents; Bone Diseases, Metabolic; Breast Neoplasms; Chemotherapy, Adjuvant; Diphosphonates; Drug Administration Schedule; Female; Follow-Up Studies; Humans; Imidazoles; Letrozole; Lumbar Vertebrae; Middle Aged; Nitriles; Osteoporosis; Triazoles; Zoledronic Acid	2016
Evaluation of BP-ONJ in osteopenic and healthy sheep: comparing ZTE-MRI with µCT. Dento maxillo facial radiology, 2016, Volume: 45, Issue:4 Topics: Animals; Bisphosphonate-Associated Osteonecrosis of the Jaw; Bone Density Conservation Agents; Bone Diseases, Metabolic; Dexamethasone; Diphosphonates; Disease Models, Animal; Female; Glucocorticoids; Image Processing, Computer-Assisted; Imaging, Three-Dimensional; Imidazoles; Magnetic Resonance Imaging; Mandibular Diseases; Ovariectomy; Periosteum; Random Allocation; Sheep; Tooth Socket; X-Ray Microtomography; Zoledronic Acid	2016
Zoledronic Acid Improves Bone Quality in the Streptozotocin-Induced Diabetes Rat through Affecting the Expression of the Osteoblast-Regulating Transcription Factors. Experimental and clinical endocrinology & diabetes : official journal, German Society of Endocrinology [and] German Diabetes Association, 2019, Volume: 127, Issue:1 Topics: Animals; Bone Density; Bone Density Conservation Agents; Bone Diseases, Metabolic; Bone Morphogenetic Protein 2; Carrier Proteins; Core Binding Factor alpha Subunits; Diabetes Mellitus, Experimental; Female; Rats; Rats, Wistar; Transcription Factors; Zoledronic Acid	2019
Bony changes in the jaws of rats treated with zoledronic acid and dexamethasone before dental extractions mimic bisphosphonate-related osteonecrosis in cancer patients. Oral oncology, 2009, Volume: 45, Issue:2 Topics: Animals; Apoptosis; Bone Density Conservation Agents; Bone Diseases, Metabolic; Dexamethasone; Diphosphonates; Disease Models, Animal; Female; Imidazoles; Injections, Intravenous; Jaw Diseases; Mandibular Diseases; Maxillary Diseases; Oral Ulcer; Osteonecrosis; Prospective Studies; Rats; Rats, Sprague-Dawley; Zoledronic Acid	2009
Severe symptomatic hypocalcemia in a patient with RDEB treated with intravenous zoledronic acid. Archives of dermatology, 2009, Volume: 145, Issue:1 Topics: Adolescent; Bone Density Conservation Agents; Bone Diseases, Metabolic; Diphosphonates; Epidermolysis Bullosa Dystrophica; Humans; Hypocalcemia; Imidazoles; Male; Zoledronic Acid	2009
The use of zoledronic acid in men receiving androgen deprivation therapy for prostate cancer with severe osteopenia or osteoporosis. Urology, 2010, Volume: 75, Issue:5 Topics: Aged; Androgen Antagonists; Bone Density Conservation Agents; Bone Diseases, Metabolic; Diphosphonates; Gonadotropin-Releasing Hormone; Humans; Imidazoles; Male; Orchiectomy; Osteoporosis; Prostatic Neoplasms; Severity of Illness Index; Zoledronic Acid	2010
[Primary hyperparathyroidism in a patient with Paget's bone disease]. Endocrinologia y nutricion : organo de la Sociedad Espanola de Endocrinologia y Nutricion, 2010, Volume: 57, Issue:4 Topics: Adenoma; Aged; Alkaline Phosphatase; Bone Density; Bone Diseases, Metabolic; Diphosphonates; Female; Humans; Hypercalcemia; Hyperparathyroidism; Imidazoles; Osteitis Deformans; Osteoporosis; Parathyroid Hormone; Parathyroid Neoplasms; Parathyroidectomy; Radionuclide Imaging; Zoledronic Acid	2010
Editorial comment. Urology, 2010, Volume: 75, Issue:5 Topics: Androgen Antagonists; Bone Density Conservation Agents; Bone Diseases, Metabolic; Diphosphonates; Gonadotropin-Releasing Hormone; Humans; Imidazoles; Male; Orchiectomy; Osteoporosis; Prostatic Neoplasms; Severity of Illness Index; Zoledronic Acid	2010
Prolonged anti-resorptive activity of zoledronic acid: evidence from postmenopausal osteopenic women and patients with Paget's disease of bone. Clinical rheumatology, 2011, Volume: 30, Issue:1 Topics: Bone Density; Bone Density Conservation Agents; Bone Diseases, Metabolic; Diphosphonates; Female; Humans; Imidazoles; Osteitis Deformans; Osteoporosis; Postmenopause; Remission Induction; Treatment Outcome; Zoledronic Acid	2011
[Parathyroid crisis due to a cystic parathyroid adenoma]. Endocrinologia y nutricion : organo de la Sociedad Espanola de Endocrinologia y Nutricion, 2011, Volume: 58, Issue:3 Topics: Bone Density Conservation Agents; Bone Diseases, Metabolic; Calcitonin; Colectomy; Colonic Diseases; Consciousness Disorders; Cysts; Diagnostic Imaging; Diphosphonates; Emergencies; Female; Furosemide; Humans; Hypercalcemia; Hyperparathyroidism, Primary; Imidazoles; Intestinal Perforation; Kidney Calculi; Middle Aged; Parathyroid Hormone; Parathyroid Neoplasms; Parathyroidectomy; Thyroidectomy; Zoledronic Acid	2011
Comparison of skeletal complications and treatment patterns associated with early vs. delayed zoledronic acid therapy in multiple myeloma. Clinical lymphoma, myeloma & leukemia, 2011, Volume: 11, Issue:4 Topics: Aged; Bone Density Conservation Agents; Bone Diseases; Bone Diseases, Metabolic; Comorbidity; Diphosphonates; Drug Administration Schedule; Female; Fractures, Spontaneous; Humans; Hypercalcemia; Imidazoles; Kaplan-Meier Estimate; Male; Middle Aged; Multiple Myeloma; Proportional Hazards Models; Retrospective Studies; Spinal Cord Compression; Zoledronic Acid	2011
Bisphosphonate-related osteonecrosis of jaws in 3 osteoporotic patients with history of oral bisphosphonate use treated with single yearly zoledronic acid infusion. Journal of oral and maxillofacial surgery : official journal of the American Association of Oral and Maxillofacial Surgeons, 2012, Volume: 70, Issue:2 Topics: Aged; Alendronate; Bisphosphonate-Associated Osteonecrosis of the Jaw; Bone Density Conservation Agents; Bone Diseases, Metabolic; Diphosphonates; Etidronic Acid; Female; Follow-Up Studies; Humans; Ibandronic Acid; Imidazoles; Infusions, Intravenous; Mandibular Diseases; Maxillary Diseases; Middle Aged; Osteoporosis, Postmenopausal; Risedronic Acid; Tooth Extraction; Tooth Socket; Zoledronic Acid	2012
[Inflammation of the jaws during treatment with bisphosphonates]. Deutsche medizinische Wochenschrift (1946), 2011, Volume: 136, Issue:41 Topics: Administration, Oral; Aged; Alendronate; Bone Density; Bone Density Conservation Agents; Bone Diseases, Metabolic; Diphosphonates; Drug Approval; Female; Humans; Imidazoles; Infusions, Intravenous; Jaw Diseases; Opportunistic Infections; Osteomyelitis; Osteonecrosis; Osteoporosis; Pamidronate; Practice Guidelines as Topic; Risk Factors; Zoledronic Acid	2011
Zoledronic acid prevents osteopenia and increases bone strength in a rabbit model of distraction osteogenesis. Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research, 2003, Volume: 18, Issue:7 Topics: Animals; Biomechanical Phenomena; Bone and Bones; Bone Density; Bone Diseases, Metabolic; Diphosphonates; Elasticity; Imidazoles; Male; Models, Animal; Osteogenesis, Distraction; Rabbits; Stress, Mechanical; Tensile Strength; Tibia; Time Factors; Weight-Bearing; Zoledronic Acid	2003
Regarding "recommendations for zoledronic acid treatment of patients with bone metastases". The oncologist, 2005, Volume: 10, Issue:5 Topics: Bone Diseases, Metabolic; Bone Neoplasms; Clinical Trials as Topic; Creatinine; Diphosphonates; Education, Medical, Continuing; Humans; Imidazoles; Infusions, Intravenous; Kidney; Practice Guidelines as Topic; Zoledronic Acid	2005
Neuropathy-induced osteopenia in rats is not due to a reduction in weight born on the affected limb. Bone, 2006, Volume: 38, Issue:3 Topics: Alendronate; Animals; Body Weight; Bone Density; Bone Density Conservation Agents; Bone Diseases, Metabolic; Diphosphonates; Hyperalgesia; Imidazoles; Ligation; Male; Neuralgia; Physical Stimulation; Rats; Rats, Sprague-Dawley; Sciatic Nerve; Stress, Mechanical; Treatment Outcome; Zoledronic Acid	2006
Oral post-surgical complications following the administration of bisphosphonates given for osteopenia related to malignancy. Journal of periodontology, 2006, Volume: 77, Issue:4 Topics: Aged; Bone Density Conservation Agents; Bone Diseases, Metabolic; Breast Neoplasms; Diphosphonates; Female; Humans; Imidazoles; Injections, Intravenous; Jaw Diseases; Osteonecrosis; Periodontitis; Zoledronic Acid	2006
Modeling bone morphogenetic protein and bisphosphonate combination therapy in wild-type and Nf1 haploinsufficient mice. Journal of orthopaedic research : official publication of the Orthopaedic Research Society, 2008, Volume: 26, Issue:1 Topics: Animals; Bone Density Conservation Agents; Bone Diseases, Metabolic; Bone Morphogenetic Protein 2; Bone Morphogenetic Proteins; Cell Survival; Cells, Cultured; Diphosphonates; Disease Models, Animal; Drug Therapy, Combination; Energy Metabolism; Female; Femur; Haplotypes; Imidazoles; Male; Mice; Mice, Inbred C57BL; Mice, Knockout; Neurofibromatosis 1; Neurofibromin 1; Osteoblasts; Skull; Tibia; Transforming Growth Factor beta; Zoledronic Acid	2008
Prevention of strain-related osteopenia in aseptic loosening of hip prostheses using perioperative bisphosphonate. Journal of orthopaedic research : official publication of the Orthopaedic Research Society, 2008, Volume: 26, Issue:5 Topics: Animals; Arthroplasty, Replacement, Hip; Bone Density; Bone Density Conservation Agents; Bone Diseases, Metabolic; Diphosphonates; Female; Hip Joint; Imidazoles; Locomotion; Microradiography; Prosthesis Failure; Random Allocation; Sheep; Stress, Mechanical; Zoledronic Acid	2008
Zoledronate (CGP 42'446), a bisphosphonate, protects against metaphyseal intracortical defects in experimental inflammatory arthritis. Journal of orthopaedic research : official publication of the Orthopaedic Research Society, 1997, Volume: 15, Issue:6 Topics: Animals; Arthritis; Bone Diseases, Metabolic; Carrageenan; Diphosphonates; Femur; Image Processing, Computer-Assisted; Imidazoles; Porosity; Rabbits; Stress, Mechanical; Zoledronic Acid	1997
Zoledronate prevents the development of absolute osteopenia following ovariectomy in adult rhesus monkeys. Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research, 1998, Volume: 13, Issue:11 Topics: Absorptiometry, Photon; Analysis of Variance; Animals; Biomarkers; Bone Density; Bone Diseases, Metabolic; Bone Resorption; Diphosphonates; Female; Imidazoles; Macaca mulatta; Ovariectomy; Regression Analysis; Zoledronic Acid	1998